P749: A comparative analysis of low bioavailability steroids in inducing clinical response and remission in ulcerative colitis: Budesonide MMX as the safest optionECCO '18 Vienna
2018
P750: Predictors of quick remission after cyclosporine A therapy in Paediatric ulcerative colitisECCO '18 Vienna
2018
P751: Time course of the incidence and magnitude of anti-drug antibodies to adalimumab and ABP 501 among patients on concomitant immunomodulatory therapyECCO '18 Vienna
2018
P752: Oral once daily budesonide granules rapidly induce clinical remission in Lymphocytic Colitis: A double-blind, double-dummy, multi-centre, randomised trialECCO '18 Vienna
2018
P753: Vedolizumab trough levels during induction in IBD patients: A longitudinal observational retrospective studyECCO '18 Vienna
2018
P755: Safety, efficacy, and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-TNFECCO '18 Vienna
2018
P756: Comorbidities in adolescents with inflammatory bowel disease: Findings from a population-based cohortECCO '18 Vienna
2018
P757: Long-term effectiveness and safety of adalimumab based on Crohn’s disease duration: Results from the PYRAMID registryECCO '18 Vienna
2018
P759: Ustekinumab as rescue treatment in therapy-refractory or -intolerant ulcerative colitisECCO '18 Vienna
2018
P760: Monitoring of laboratory parameters during thiopurine maintenance therapy in patients with inflammatory bowel disease: An unnecessary burden?ECCO '18 Vienna
2018
P761: IFX dose-escalation strategy based on a population PK model in IBD patients with secondary loss of responseECCO '18 Vienna
2018
P762: GO-CARE: A prospective multi-centre observational study of golimumab effectiveness and quality of life in a real-life UC patient population in ItalyECCO '18 Vienna
2018
P763: Quality of life in Paediatric inflammatory bowel disease Patient: How well do we understand patients?ECCO '18 Vienna
2018